Researchers have found two different compounds that can block malaria transmission when added to pre-existing treatment regimes. Credit: turkletom

Emergent BioSolutions has reported positive findings from the interim analysis of a Phase II clinical trial being conducted to assess its chikungunya virus-like particle (CHIKV-VLP) vaccine candidate.

According to the data, around 98% of the trial subjects who received a single dose of the vaccine generated a neutralising antibody response against the virus by day seven.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The response was observed to be sustained through the six-month visit.

Spread via mosquitoes, chikungunya virus is characterised by fever, joint pain, headache, muscle pain, joint swelling or rash. The infection does not currently have a preventive or treatment therapy.

“The Phase II trial assessed the safety and immunogenicity of the CHIKV-VLP vaccine candidate in multiple dosing regimens.”

Emergent BioSolutions licensed the CHIKV-VLP chikungunya virus vaccine candidate from the US National Institutes of Health’s National Institute of Allergy and Infectious Diseases.

Virus-like particle (VLP) vaccines are multi-protein products with organisation and conformation similar to that of natural viruses. However, VLP vaccines lack the viral genome and are intended to stimulate a strong immune response and improve antibody generation.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Prior research demonstrated that VLP vaccines are highly immunogenic, safe and usually induce high titer neutralising antibodies to protect against the virus.

The parallel-group, randomised, double-blind, dose-finding Phase II trial assessed the safety and immunogenicity of the CHIKV-VLP vaccine candidate in multiple dosing regimens.

It was performed in a total of 415 healthy adults at three sites in the US. Subjects received a one or two-dose series of the investigational vaccine with or without an adjuvant over four weeks.

Following one dose, 74%-98% of the participants had seroconversion within seven days. All subjects experienced seroconversion by 28 days after the last dose.

The vaccine candidate was found to be well-tolerated without any significant vaccine-related safety concerns.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact